Upcoming Conference Calls, FDA Approvals, NDA Updates, and Donations - Analyst Notes on The Medicines Company, Bio-Rad, Spectrum Pharmaceuticals, Insys Therapeutics and Hanger
NEW YORK, July 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding The Medicines Company (NASDAQ: MDCO), Bio-Rad Laboratories, Inc. (NYSE: BIO), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), Insys Therapeutics Inc (NASDAQ: INSY) and Hanger Inc (NYSE: HGR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4741-100free.
The Medicines Company Analyst Notes
On July 9, 2014, The Medicines Company announced the schedule of its quarterly conference call to discuss its Q2 2014 financial results, operational developments, and outlook for 2014 on Wednesday, July 23, 2014, at 8:30 a.m. ET. According to the Company, the call will be webcast live on its website, where a replay of the webcast will also be accessible from 11:30 a.m. ET after the conference call until July 30, 2014. The full analyst notes on The Medicines Company are available to download free of charge at:
Bio-Rad Laboratories, Inc. Analyst Notes
On July 7, 2014, Bio-Rad Laboratories, Inc. (Bio-Rad) announced that it will host a conference call to discuss its Q2 2014 financial results on Tuesday, August 5, 2014, at 2:00 p.m. PT (5:00 p.m. ET), followed by the release of the results on the same day, after the market closes. According to the Company, a live webcast of the call will be accessible through its website, where a replay will also be available for up to a year. The full analyst notes on Bio-Rad are available to download free of charge at:
Spectrum Pharmaceuticals, Inc. Analyst Notes
On July 7, 2014, Spectrum Pharmaceuticals, Inc. (Spectrum Pharmaceuticals) announced that it received Accelerated Approval from the FDA for Beleodaq™ (belinostat) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). According to the Company, this indication was approved based on data from BELIEF trial in 120 evaluable patients, refractory to or those who had failed at least one prior systematic therapy. The Company added that in this trial, Beleodaq was associated with hematologic toxicity, infections, hepatotoxicity, tumor lysis syndrome, gastrointestinal toxicity, and embryo-fetal toxicity. Rajesh C. Shrotriya, M.D., Chairman and CEO, Spectrum Pharmaceuticals said, "This FDA approval enables us to help address this unmet medical need, and provide a new treatment option for patients with this difficult-to-treat and ultimately fatal disease. We will be able to effectively leverage our existing Hematology clinical and sales infrastructure to expedite the launch of Beleodaq." The full analyst notes on Spectrum Pharmaceuticals are available to download free of charge at:
Insys Therapeutics Inc Analyst Notes
On July 8, 2014, Insys Therapeutics Inc (Insys Therapeutics) announced the completion of a human abuse study for Dronabinol Oral Solution, its propriety, orally administered liquid formulation of the synthetic cannabinoid dronabinol which is in development for the treatment of chemotherapy induced nausea and vomiting (CINV) and anorexia in association with weight loss in patients with AIDS. Insys Therapeutics reported that this human abuse study was required by the U.S. Drug Enforcement Agency (DEA) for scheduling classification purposes. The Company plans to file the New Drug Application (NDA) for Dronabinol Oral Solution in Q3 2014. Michael L. Babich, President and CEO, Insys Therapeutics said, "We are very excited about Oral Dronabinol Solution, which is the culmination of significant research and which we believe has distinct advantages over the current formulation of dronabinol in a soft gelatin capsule, including more consistent bioavailability, faster onset of action and more flexible dose." The full analyst notes on Insys Therapeutics are available to download free of charge at:
Hanger Inc Analyst Notes
On July 2, 2014, Hanger Inc (Hanger) reported that it has donated $100,000 for establishment of the 2014-2015 Hanger Kids Scholarship to Camp No Limits, a non-profit camp for children with limb loss or limb difference. According to the Company, the amount will be distributed to one hundred $1,000-each scholarships that will cover attendance cost, lodging, meals, and included activities for kids with amputations or limb differences, plus an accompanying parent or guardian at any of the Camp No Limits camps nationwide in 2014 and 2015. Vinit Asar, President and CEO, Hanger said, "Over the past 10 years, through their volunteerism with Camp No Limits, our employees have witnessed the incredible benefit this special camp provides for children with limb loss or limb difference and their families. We are delighted to support their efforts and are happy this scholarship will help even more children and their families get to camp." The full analyst notes on Hanger are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review